• 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008

The journal «ONCOSURGERY» 2012, Vol.4, No 3

Magnetic Resonance imaging in the evaluation of efficiency of neoadjuvant chemoradiotherapy in patients with cervical cancer

Rubtsova NA1, Boyko AV2, Demidova LV2, Andreeva YuYu3

PA Herzen Moscow Cancer Research Institute,
1) Department of Rentgendiagnostics,
2) Department of Radiotherapy,
3) Department of Pathomorphology,
Moscow, Russia
Contact: Rubtsova NA, e-mail:

Objective. To define the possibility for prognosing of efficiency of neoadjuvant chemoradiotherapy (n-CRT) at patients with invasive cervical cancer based on perfusion tumor characteristics at a magnetic resonance imaging tomography (MRI) with dynamic intravenous contrast enhancing.

Material and Methods: 43 patients with invasive cervical cancer were examined, the majority of patients were with stage IIB-IIIB (FIGO), histologically (93%) – squamous cell cancer. For the definition of local staging cervical cancer all patient were examined by MRI with intravenous contrast dynamic enhancing (with subsequent estimation of perfusion indicators) before and two weeks after n-CRT in the preoperative period.

Results of the graphic analysis displays dynamic contrasting before n-CRT and given postoperative histological materials, correlation between level of heterogeneity of perfusion and degree of therapeutic response were established. For heterogeneity of up to 10% good efficiency of n-CRT (IV degree of therapeutic response) was observed. For heterogeneity fluctuations in a tumor of 10-20% the efficacy of treatment was average (II-III degree of therapeutic response), and for high values of heterogeneity perfusion in a tumor (more than 20%) the efficiency of n-CRT was low.

Conclusions. The obtained results of research show the possibility for prognosing of n-CRT efficiency in patients with cervical cancer based on perfusion data, calculated at MRI with dynamic contrast enhancing.

KEY WORDS: MRI, cervical cancer, neoadjuvant chemoradiotherapy, estimation of efficiency, prognosing efficiency.

References

  1. Novikova EG. et al. Oncology. National leadership edited Acad. RAMS VI Chissova Acad. RAS and RAMS NI Davydov. M. Geotar-media, 2008.
  2. Morhov KU, Kuznecov VV. Lectures on oncogynecology edited MI Davydova, VV Kuznecova. M.: 2009; 199-284
  3. DiSaia PJ, Creasman WT. Clinical gynecologic oncology – 7-th ed. Mosby Elsevier. 2007; 812.
  4. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Randy E. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340: 1137-1143.
  5. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Depppe G, Maiman MA. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340: 1144-1153.
  6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999; 340: 1154-1161.
  7. Wagenaar HC, et al. Tumour diameter and volume assessed by MRI in prediction of outcome for invasive cervical cancer. Gynecol Oncol. 2001; 82: 474-482.
  8. Seki H., Azumi R, Kimura M, et. al. Stromal invasion by carcinoma of cervix: Assessment with dynamic MR imaging. AJR. 1997; 168: 1579-1585.
  9. Postema S, Pattynama P, van Rijswijk C, Trimbos B. Cervical Carcinoma: Can Dynamic Contrast-enhanced MRI Help Predict Tumor Aggressiveness? Radiology. 1999; 210: 217-220.
  10. Hulse P, Carrington B. MRI manual of pelvic cancer. Martin Dunitz Taylor & Francis group. 2004; 23-25.
  11. Mayr N, Yuh W, Jajoura D. Ultra Early Predictive Assay for Treatmrnt Failure Using Functional MRI and clinical Prognostic Parameters in Cervical Cancer. AJR. 2010; 116: 903-912.

P. 41-45

Publishers
«Oncokhirurgia Info»

10 Vostochnaia ul., suite 16, Moscow, 115280
Tel./fax: +7(499) 426-46-22
Tel.: +7(915) 356-03-07
E-mail:
URL: oncosurgery.oncology.ru


РСХО